What the hospital CMO role owns now

A healthcare CMO in India now owns demand generation, brand, digital, CRM and doctor-facing marketing, not just campaigns and hoardings. This piece maps where that mandate genuinely stops, at the medical director’s clinical calls and the CFO’s pricing decisions, and how the scope differs between a single hospital and a group.

Ask a board member what a hospital CMO owns and you will likely hear “marketing” — a website, a hoarding campaign, perhaps the Instagram account. Ask the CMO the same question and the list runs to a dozen items, several of which nobody budgeted a headcount for. I have sat on both sides of that gap — as VP Digital reporting into a CMO, and earlier as the CMO-equivalent for a multi-city children’s hospital chain — and the gap is not a communication problem. The role changed faster than the job description did.

A decade ago the hospital marketing head bought print space, ran a handful of health camps, and passed a lead sheet to sales once a month. That job barely exists anymore. What replaced it is a function that runs demand generation across paid and organic channels, owns the brand promise across every unit, runs the CRM and patient communication stack end to end, manages a doctor-facing marketing programme most boards do not know exists, does the PR and reputation work that used to sit with the CEO’s office, and in a meaningful minority of groups, runs the international patient desk as well. That is not scope creep. That is the actual job now.

The confusion is rarely about what the CMO does. It is about what people assume sits somewhere else, and — more consequentially — about the handful of things a good CMO should not touch even when asked to. Get the boundary wrong in either direction, hoarding too much or ducking too much, and the rest of the executive committee spends the year renegotiating turf that should have been settled in the first ninety days.

What the mandate actually covers today

Strip away the title and look at what a functioning hospital CMO signs off on in a typical month. In most groups I have watched closely, it lands on five or six areas, not one:

• Demand generation across search, social, listings, camps and referral partnerships
• Brand — the promise, the tone, and how consistently every unit represents it
• The digital front door: website, app, chatbot and the contact centre’s scripts and SLAs
• CRM and patient communication — recall, reminders, post-discharge follow-up, WhatsApp threads
• Doctor-facing marketing — the material and cadence that keeps referring doctors engaged
• PR and reputation, including how the group responds when something goes wrong publicly

A fair number of groups also route the international patient desk through marketing, on the logic that it is a demand-and-conversion problem before it is anything else — coordinating enquiries, visas, travel and the first clinical opinion, then handing off once the patient is on the ground. Not every group makes that call, and it is worth asking explicitly rather than assuming it by default; the desk sits closer to operations in some organisations, and that is a defensible choice too.

A single hospital versus a multi-unit group

The scope above holds for a single flagship hospital, but the shape of the job changes considerably once there are three, five or a dozen units under one brand. A single-hospital CMO is close to the ground — approving the local camp calendar, sitting in on doctor onboarding, reviewing the week’s enquiry volume by specialty. Most of the work is activation.

A group CMO does much less activation directly and much more architecture: a shared CRM instance rather than five disconnected ones, a common brand system that a new unit can pick up in weeks rather than build from scratch, and a centralised content and paid-media engine that individual units draw on instead of running their own agencies. Getting this right usually means building the digital team as a shared service that sits above any one unit, reporting into the CMO or a peer digital head, rather than as marketing headcount scattered across hospitals with no common tooling or standards. The trade-off is real: centralisation is faster and cheaper at scale, and it is also the thing unit heads resent most in year one, because it takes decisions away from people who used to make them locally.

Where the mandate stops: the medical director’s line

The clearest boundary in the job, and the one most often crossed by an overconfident CMO, sits with clinical outcomes messaging. A CMO can and should shape how a specialty’s story gets told — the patient journey, the reassurance, the access — but the specific clinical claims inside that story are not the CMO’s to write or approve alone. Survival rates, complication rates, comparative outcome language: that content is authored or at minimum sign-off-reviewed by the medical director and clinical governance, every time, with no exceptions for a campaign deadline.

This is not deference for its own sake. It is that a marketing function, however well-intentioned, does not carry the clinical judgement to know when an outcome claim is accurate, current, and safely generalisable to the audience reading it. I have seen a strong campaign get pulled two days before launch because a clinician flagged a claim that was technically true for one surgeon’s caseload and misleading as a general statement. That is the system working, not failing.

Doctor referral networks sit in similar territory. The CMO owns the relationship cadence — the newsletters, the CME invitations, the account-management rhythm that keeps a referring doctor engaged — but credentialing, privileging and anything that touches a doctor’s clinical standing stays with the medical director’s office. Marketing nurtures the relationship; it does not decide who gets to operate.

Where the mandate stops: the CFO’s line

The second hard boundary sits with pricing. A CMO should have a strong, well-evidenced view on pricing — what the demand data says about elasticity, what a package needs to include to convert, where a price point is quietly losing volume to a competitor down the road. That view should be in every pricing conversation. It should not be the CMO’s signature that sets the number.

The discipline here is close to what a digital head owes the CFO on any commercial decision: bring the evidence, make the case, accept that the final call belongs to whoever owns the P&L and the margin consequences. A CMO who starts setting prices unilaterally, even with good data, is taking on accountability for a line item that finance and unit leadership have to defend to the board — and that almost never ends well for the CMO when the number turns out wrong.

What gets miscategorized as marketing that it should not own

Beyond the two hard boundaries above, a few things get handed to marketing by default because nobody else claims them, and the CMO is usually right to push back:

• Clinical outcomes messaging and any comparative claim against another provider
• Setting the price itself, as opposed to informing it with demand evidence
• Doctor credentialing and clinical privileging decisions
• Patient safety communication during an active clinical incident, which belongs with clinical governance and only moves to PR once the clinical response is settled
• Capacity and scheduling decisions, which sit with operations even when marketing is generating the demand that fills the capacity

The instinct to say yes to all of it is understandable — declining scope can look like avoiding work. But taking on a decision you do not have the standing or the information to make well is a worse outcome for the patient and a worse position for the CMO than saying, clearly, whose call it actually is. This scoping discipline is exactly what shows up, a few months later, in the CMO annual plan brought to the board — a narrative of demand and margin, not a list of channels.

The India-specific texture of the job

None of the above is unique to India, but the texture around it is. WhatsApp is now the primary channel for appointment reminders, reports and post-discharge follow-up in most urban and Tier 2 markets, which means the CMO’s CRM decisions are really WhatsApp Business API decisions — template approval, opt-in management, response SLAs — more than they are decisions about a traditional email platform. Doctor referral networks matter more in India than in most markets the CMO’s counterparts elsewhere are managing, particularly once a group expands into Tier 2 catchments, where a handful of respected local doctors can still move more volume than any digital campaign.

Consent has also become a live operational question rather than a legal footnote. DPDP-era obligations mean the CMO’s CRM and campaign teams need a defensible record of what a patient consented to and when, not a blanket assumption that a phone number collected at registration licences every future message. And the NMC’s advertising guidelines shape what can be claimed in any patient-facing material — no comparative superiority claims, no unverifiable outcome statistics, no language that reads as solicitation. A CMO who has internalised these constraints writes tighter, more defensible campaigns from the start, rather than discovering the limits after a complaint.

The doctor-facing side nobody puts in the job description

Patient marketing gets all the attention in a board deck. Doctor-facing marketing is quieter and, in a group that depends on referral volume, just as consequential. This is not the same job as patient demand generation — it runs on a different cadence, a different content type, and a different measure of success.

A working doctor-facing programme needs its own content calendar — case studies, CME sessions, specialty updates — built for a doctor’s attention span and scepticism, not repurposed patient content with the tone turned down. It needs an account-management rhythm, often run through the same CRM as patient communication but on separate lists and separate cadences, so a referring doctor is not getting the same WhatsApp broadcast as a patient. And it needs its own measure of health: referral volume and consistency by doctor, not clicks or impressions, reviewed with the same seriousness as the patient acquisition funnel.

If you are stepping into this role next quarter

A CMO who wants the path to CEO treats this scoping exercise as the first real test, not paperwork to get through before the interesting work starts. The order that works:

• Get the medical director and the CFO in a room in your first two weeks and agree the two boundaries above explicitly, in writing, before a campaign forces the conversation
• Audit what you actually own today against what the org chart says you own — the gap is usually larger than expected, in either direction
• Map the demand funnel end to end, including the doctor-facing side, before committing to a channel strategy
• Decide, deliberately, whether the international patient desk sits with you or with operations — do not let it default by inertia
• Bring your first board narrative as a demand-and-margin case, not a channel update

Every one of these conversations is uncomfortable in year one. They get easier once the medical director and the CFO see that you are as quick to decline scope you should not have as you are to claim scope you should.

The CMO who lasts in this role is not the one with the biggest budget. It is the one whose boundaries the rest of the executive committee stopped questioning by month four.

Questions people ask